What's happening?

Xue Chen, Haidong Yao, Muhammad Kashif, Gwladys Revêchon, Maria Eriksson, Jianjiang Hu, Ting Wang, Yiran Liu, Elin Tüksammel, Staffan Strömblad, Ian M Ahearn, Mark R Philips, Clotilde Wiel, Mohamed X Ibrahim, Martin Bergo

One of the main problems that is holding back the widespread adoption of self-administration for injectable formulations, is that many of the available devices are unable to deliver the drug through a needle that is fine enough to be acceptable to the patient. This is particularly true for highly viscous formulations. 

Inhalation products are some of the most complicated and challenging drug dosage forms to develop and manufacture, primarily due to the potential interactions between the formulation and the delivery device at each stage in the development and manufacturing process, as well as when it reaches the end user. 

Vaccine production is a very complex process, making specialist expertise vital to ensuring both the safety and efficacy of the final product. However, depending on the type of vaccine, different approaches are required.

Inhalation products are extremely complex to develop and manufacture, and it is important to understand potential interactions between the formulation and the delivery device throughout the development stages.

User-friendly drug design is about so much more than improving delivery devices. When it comes to reducing the administration burden for patients, modified-release formulations drugs can also help.

All eyes have been on the pharmaceutical industry throughout 2020 and the start of 2021 - assessing its capacity to provide an answer to a truly global challenge. 

The pandemic has highlighted vulnerabilities in the industry’s highly globalized supply chain.

Tackling the challenges of combination drug development can be difficult. There are many obstacles facing developers of combination inhalation treatments, so what are they and how can they be overcome?

Arnaud C. Tiberghien, Philip W. Howard, William R. F. Goundry, Marc McCormick and Jeremy S. Parker. 
  Recipharms Elfyn Jones and Mikael Hillgren supported with the upscale of intermediate that made this article possible.

Oral solid dosage (OSD) products remain the largest segment of the pharmaceutical market. Oral solids continue to be the most commonly used delivery vehicle to get drugs to patients. There are three main factors for this: they are cost-effective, relatively easy to manufacture, and most importantly, are patient friendly.